В. А. Марков

3.3k total citations · 1 hit paper
38 papers, 814 citations indexed

About

В. А. Марков is a scholar working on Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and Imaging and Surgery. According to data from OpenAlex, В. А. Марков has authored 38 papers receiving a total of 814 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Cardiology and Cardiovascular Medicine, 8 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Surgery. Recurrent topics in В. А. Марков's work include Acute Myocardial Infarction Research (17 papers), Cardiac Imaging and Diagnostics (8 papers) and Healthcare Systems and Public Health (4 papers). В. А. Марков is often cited by papers focused on Acute Myocardial Infarction Research (17 papers), Cardiac Imaging and Diagnostics (8 papers) and Healthcare Systems and Public Health (4 papers). В. А. Марков collaborates with scholars based in Russia, Germany and United States. В. А. Марков's co-authors include Frank Misselwitz, Pascual Bordes, Paul Burton, Rohan Poulter, C. Michael Gibson, Eugene Braunwald, Satishkumar Mohanavelu, Leonard Oppenheimer, V. Hricak and Adam Witkowski and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

В. А. Марков

30 papers receiving 786 citations

Hit Papers

Rivaroxaban versus placebo in patients with acute coronar... 2009 2026 2014 2020 2009 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial
    2009 488 citations Eugene Braunwald, Satishkumar Mohanavelu et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
В. А. Марков Russia 7 736 272 122 93 49 38 814
Gail Berman United States 6 398 0.5× 124 0.5× 131 1.1× 28 0.3× 132 2.7× 7 476
Donald Palisaitis Canada 14 773 1.1× 288 1.1× 320 2.6× 67 0.7× 103 2.1× 32 910
Guillaume Cayla France 14 1.0k 1.4× 227 0.8× 551 4.5× 73 0.8× 71 1.4× 32 1.1k
Ute Priglinger Austria 10 276 0.4× 96 0.4× 105 0.9× 24 0.3× 88 1.8× 17 556
Nina Vene Slovenia 14 334 0.5× 158 0.6× 47 0.4× 20 0.2× 69 1.4× 26 476
Jae Youn Moon South Korea 15 396 0.5× 64 0.2× 271 2.2× 96 1.0× 22 0.4× 44 527
Christine Zürn Germany 10 772 1.0× 144 0.5× 387 3.2× 112 1.2× 36 0.7× 18 1.0k
Drew A. Purdy United States 3 1.3k 1.7× 411 1.5× 661 5.4× 63 0.7× 83 1.7× 4 1.4k
Claudio Laudani Italy 11 278 0.4× 51 0.2× 170 1.4× 69 0.7× 28 0.6× 40 420
Rosemary Ecob United Kingdom 7 523 0.7× 199 0.7× 213 1.7× 10 0.1× 63 1.3× 7 593

Countries citing papers authored by В. А. Марков

Since Specialization
Citations

This map shows the geographic impact of В. А. Марков's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by В. А. Марков with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites В. А. Марков more than expected).

Fields of papers citing papers by В. А. Марков

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by В. А. Марков. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by В. А. Марков. The network helps show where В. А. Марков may publish in the future.

Co-authorship network of co-authors of В. А. Марков

This figure shows the co-authorship network connecting the top 25 collaborators of В. А. Марков. A scholar is included among the top collaborators of В. А. Марков based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with В. А. Марков. В. А. Марков is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Крылов, А. Л., et al.. (2019). Two-Stage Revascularization in Patients with Acute Myocardial Infarction and Massive Coronary Thrombosis. Kardiologiia. 59(2). 5–9. 3 indexed citations
3.
Ryabov, V. V., et al.. (2018). Quality of care for patients with myocardial infarction with ST segment elevation. real clinical practice of the invasive center.. Clinical Medicine (Russian Journal). 96(6). 506–511. 1 indexed citations
4.
5.
6.
7.
8.
Ryabov, V. V., et al.. (2016). CASE OF PSEUDOCORONARY PRESENTATION OF MYOCARDITIS WITH ST SEGMENT ELEVATION. Russian Journal of Cardiology. 95–96. 1 indexed citations
9.
10.
Марков, В. А., et al.. (2015). PRIMARY ANGIOPLASTICS AND PHARMACOINVASIVE REPERFUSION IN MYOCARDIAL INFARCTION: IMPACT ON CLINICAL OUTCOMES AND NO-REFLOW PHENOMENON. SHILAP Revista de lepidopterología. 14(1). 17–17. 4 indexed citations
11.
Марков, В. А., et al.. (2015). CORONARY REPERFUSION IN ST ELEVATION MYOCARDIAL INFARCTION: PROBLEMS AND SOLUTIONS. SHILAP Revista de lepidopterología. 53–58. 1 indexed citations
12.
Ryabov, V. V., et al.. (2014). HEART-TYPE FATTY ACID BINDING PROTEIN-BASEDExPRESS TEST IN THE DIAGNOSTICS OF ACUTE MYOCARDIAL INFARCTION. Russian Journal of Cardiology. 84–88.
13.
Марков, В. А., et al.. (2012). FORTELYZIN IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION. Medical academic journal. 12(1). 80–86. 3 indexed citations
14.
Плотников, М. Б., et al.. (2009). Antithrombotic and Thrombolytic Effects of a New Proteolytic Preparation Trombovazim (Russia). Bulletin of Experimental Biology and Medicine. 147(4). 438–440. 2 indexed citations
15.
Braunwald, Eugene, Satishkumar Mohanavelu, Paul Burton, et al.. (2009). Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. The Lancet. 374(9683). 29–38. 488 indexed citations breakdown →
16.
Карпов, Р. С., С. В. Попов, В. А. Марков, et al.. (2005). Autologous Mononuclear Bone Marrow Cells during Reparative Regeneratrion after Acute Myocardial Infarction. Bulletin of Experimental Biology and Medicine. 140(5). 640–643. 34 indexed citations
17.
Марков, В. А., et al.. (2004). [The protective effect of trimetazidine on the myocardium against reperfusion injury during thrombolytic therapy of acute infarction].. PubMed. 67(2). 27–30. 3 indexed citations
18.
Марков, В. А., et al.. (2002). Cardioprotective Effect of Trimetazidine during Thrombolytic Therapy in Patients with Acute Myocardial Infarction. Bulletin of Experimental Biology and Medicine. 134(6). 559–561. 4 indexed citations
19.
Марков, В. А., et al.. (1989). [Relation between the systemic fibrinolytic status and coronary reperfusion during thrombolytic therapy with streptokinase of patients with acute myocardial infarction].. PubMed. 29(9). 92–4.
20.
Belenkov, Yu. N., et al.. (1986). Use of Electrical Pacing and Automatic Cardioversion Defibrillation for Normal Cardiac Function Recovery. Pacing and Clinical Electrophysiology. 9(6). 1349–1355. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gail Berman Breakdown of academic impact, for papers by Donald Palisaitis Breakdown of academic impact, for papers by Guillaume Cayla Breakdown of academic impact, for papers by Ute Priglinger Breakdown of academic impact, for papers by Nina Vene Breakdown of academic impact, for papers by Jae Youn Moon Breakdown of academic impact, for papers by Christine Zürn Breakdown of academic impact, for papers by Drew A. Purdy Breakdown of academic impact, for papers by Claudio Laudani Breakdown of academic impact, for papers by Rosemary Ecob
Rankless by CCL
2026